How do I diagnose and treat influenza A (H3) infection, including management of high‑risk patients?

Diagnosis and Management of Influenza A (H3N2) Infection

For patients presenting with acute influenza-like illness and fever >38°C within 48 hours of symptom onset, initiate oseltamivir 75 mg orally twice daily for 5 days immediately without waiting for laboratory confirmation. 1, 2, 3

Diagnostic Approach

When to Test for Influenza

During active influenza season:

• Test all high-risk patients (immunocompromised, elderly, chronic cardiopulmonary disease, pregnant) presenting with influenza-like illness, pneumonia, or even nonspecific respiratory symptoms like cough without fever if results will influence management 1
• Test patients with acute exacerbations of asthma, COPD, or heart failure, as influenza commonly triggers decompensation of underlying conditions 1
• Test all hospitalized patients with acute respiratory illness or worsening chronic disease on admission 1
• Testing in previously healthy outpatients is optional but can reduce unnecessary antibiotics and guide household contact prophylaxis 1

During low influenza activity:

• Consider testing primarily in immunocompromised and high-risk patients with acute respiratory symptoms 1

Clinical Features of H3N2 Specifically

H3N2 infections tend to be more severe than H1N1 or influenza B, with higher fever (mean 38.6°C), more pronounced leukopenia, and elevated inflammatory markers 4. Patients typically present with abrupt onset of high-grade fever, myalgia, headache, malaise, nonproductive cough, sore throat, and nasal discharge 5, 6. Unlike influenza B, gastrointestinal symptoms are less prominent in H3N2 4.

Antiviral Treatment

Initiation Criteria and Timing

Start oseltamivir 75 mg orally twice daily for 5 days if ALL three criteria are met: 2, 3

1. Acute influenza-like illness
2. Fever >38°C (adults) or >38.5°C (children)
3. Presenting within 48 hours of symptom onset

Critical exceptions where the 48-hour window can be extended: 2, 3, 7

• Hospitalized or severely ill patients
• Immunocompromised patients
• Elderly patients at high risk for complications
• These patients may still benefit from antiviral therapy even after 48 hours 2, 3, 7

Dose adjustments: 7

• For creatinine clearance <30 mL/min: reduce to 75 mg once daily
• Alternative agent: zanamivir (inhaled) for patients unable to take oseltamivir 1, 2

Common Pitfall

Do not withhold oseltamivir from elderly or immunocompromised patients based solely on absence of fever—these populations may not mount adequate febrile responses but remain at high risk for severe complications 2, 7. Do not prescribe oseltamivir to outpatients presenting ≥48 hours after symptom onset with uncomplicated illness, as clinical benefit is only established within the first 48 hours 2.

Antibiotic Management: A Stratified Approach

Previously Healthy Adults WITHOUT Pneumonia

Antibiotics are NOT routinely required for uncomplicated influenza or acute bronchitis complicating influenza 1, 2, 3. However, strongly consider antibiotics if: 1, 2

• Recrudescent fever after initial improvement (suggests bacterial superinfection)
• Increasing breathlessness or worsening symptoms
• Symptoms not settling after 2 days

First-line oral antibiotics when indicated: 1, 2

• Co-amoxiclav 625 mg three times daily OR
• Doxycycline 200 mg loading dose, then 100 mg once daily
• Alternative for penicillin allergy: clarithromycin 500 mg twice daily or erythromycin 500 mg four times daily 1, 2
• Duration: 7 days for uncomplicated cases 2

Patients with COPD or Severe Pre-existing Illness

Antibiotics are recommended even without clear pneumonia, as these patients are at high risk for bacterial superinfection 1. Use the same first-line regimens as above 1, 2.

Influenza-Related Pneumonia (Community Management)

For non-severe pneumonia managed at home: 1, 2

• Co-amoxiclav 625 mg three times daily OR doxycycline (as above)
• These agents provide essential coverage for Staphylococcus aureus, a key pathogen in influenza-associated bacterial pneumonia, in addition to Streptococcus pneumoniae and Haemophilus influenzae 1, 2
• Duration: 7 days 2

For severe pneumonia requiring hospitalization: 2

• Immediate IV combination therapy (within 4 hours of admission):
  • IV co-amoxiclav OR 2nd/3rd generation cephalosporin (cefuroxime or cefotaxime) PLUS
  • Macrolide (clarithromycin or erythromycin)
• Switch to oral antibiotics when: clinical improvement occurs, temperature normal for 24 hours, and oral route feasible 2
• Duration: 10 days for severe, microbiologically undefined pneumonia; 14-21 days if S. aureus or Gram-negative bacteria confirmed or strongly suspected 2

Critical Antibiotic Pitfall

Azithromycin monotherapy is inadequate for influenza-related pneumonia because it lacks reliable coverage for S. aureus 2. Co-amoxiclav or doxycycline must be used as first-line therapy 1, 2.

Severity Assessment and Hospitalization Criteria

Calculate CURB-65 score immediately: 3, 7

• Confusion
• Urea elevation
• Respiratory rate ≥30/min
• Blood pressure (SBP <90 or DBP <60 mmHg)
• Age ≥65 years

Interpretation: 3, 7

• Score 0-1: Consider home treatment with close follow-up
• Score 2: Short inpatient stay or hospital-supervised outpatient treatment
• Score ≥3: Hospitalization required

Additional urgent hospitalization criteria: 3

• Bilateral lung infiltrates on chest X-ray
• Oxygen saturation <90%
• Respiratory distress or inability to maintain oral intake

Special Populations

Children

• Children <1 year and all high-risk children must be assessed by a physician 1, 3
• Children aged 1-7 years may be seen by nurse or GP; those ≥7 years by community health team 1, 3
• Aspirin is absolutely contraindicated in children <16 years due to Reye's syndrome risk 1, 2, 3
• Use paracetamol or ibuprofen for fever control 1, 2

Elderly and Immunocompromised

• May not mount adequate febrile response but remain eligible for antiviral treatment 2, 3, 7
• Automatically at high risk and warrant closer monitoring 7
• May present with atypical symptoms including confusion without prominent fever 7
• Standard 48-hour window for antivirals can be extended in these populations 2, 7

Supportive Care

All patients should receive: 2, 3

• Paracetamol or ibuprofen for fever, myalgias, and headache
• Rest and adequate hydration
• Avoidance of smoking
• Consider short course of topical decongestants, throat lozenges, saline nose drops 1

Red Flags Requiring Immediate Re-evaluation

Instruct patients to return or call immediately for: 2, 3, 7

• Shortness of breath at rest or increasing dyspnea
• Painful or difficult breathing
• Coughing up bloody sputum
• Recrudescent fever (fever returning after initial improvement—highly suggestive of bacterial superinfection)
• Altered mental status or confusion
• Inability to maintain oral intake
• Chest pain

Complications to Monitor

Neurological Complications

• Encephalitis and encephalopathy can occur, particularly in children 1
• Bilateral thalamic involvement is characteristic on MRI 1
• Important differential: increased risk of meningococcal disease following influenza infection 1

Other Complications

• Myositis (predominantly affects calf muscles in school-aged children; rhabdomyolysis rare) 1
• Myocarditis and pericarditis (rare, more common in those with underlying conditions) 1
• Secondary bacterial pneumonia (most common serious complication) 1, 2

Infection Control

To prevent transmission: 3

• Strict hand hygiene
• Respiratory etiquette (cover coughs/sneezes)
• Avoid contact with others while symptomatic
• Remain off work while symptomatic

Prevention

Annual influenza vaccination is recommended for all persons ≥6 months of age without contraindications and is the most effective prevention strategy 1, 3. Vaccination is particularly important for healthcare workers and high-risk patients 1.